Keyphrases
Confidence Interval
100%
Overall Survival
100%
Hodgkin Lymphoma
100%
Brentuximab Vedotin
100%
Progression-free Survival
75%
Hazard Ratio
50%
Survival Benefit
50%
Doxorubicin
50%
Vinblastine
50%
Dacarbazine
50%
Disease Progression
25%
Transplantation
25%
Increased Incidence
25%
Peripheral Neuropathy
25%
Potential Gains
25%
Granulocyte Colony-stimulating Factor (G-CSF)
25%
First-line Therapy
25%
Interim Analysis
25%
Antibody-drug Conjugate
25%
Intention-to-treat
25%
Survival Estimation
25%
Subsequent Therapy
25%
5-year Follow-up
25%
Bleomycin
25%
Long-term Development
25%
CD30
25%
Febrile Neutropenia
25%
Previously Untreated
25%
Primary Prophylaxis
25%
Classic Hodgkin Lymphoma
25%
Second Cancer
25%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Hodgkin Disease
100%
Brentuximab Vedotin
100%
Progression Free Survival
75%
Doxorubicin
50%
Vinblastine
50%
Dacarbazine
50%
Granulocyte Colony Stimulating Factor
25%
Disease Exacerbation
25%
Classical Hodgkin Lymphoma
25%
Second Cancer
25%
Neuropathy
25%
Febrile Neutropenia
25%
Bleomycin
25%
Antibody Drug Conjugate
25%
Medicine and Dentistry
Overall Survival
100%
Hodgkin's Lymphoma
100%
Brentuximab Vedotin
100%
Adriamycin Bleomycin Vinblastine Dacarbazine
100%
Progression Free Survival
33%
Hazard Ratio
22%
Doxorubicin
22%
Vinblastine
22%
Dacarbazine
22%
Disease Exacerbation
11%
Intention-to-Treat Analysis
11%
Neuropathy
11%
Antibody-Drug Conjugate
11%
Classical Hodgkin Lymphoma
11%
Second Cancer
11%
Survival Estimate
11%
Febrile Neutropenia
11%
Granulocyte Colony Stimulating Factor
11%
Bleomycin
11%
Interim Analysis
11%
Immunology and Microbiology
Overall Survival
100%
Brentuximab Vedotin
100%
Progression Free Survival
75%
Granulocyte Colony-Stimulating Factor
25%
Antibody Drug Conjugate
25%